










20/09/11

Press conference

- ✎ MCI.BioVentures was launched in the year 2007.
- ✎ It is a venture capital fund investing in the most attractive companies operating in the areas of healthcare, medtech and biotechnology at startup stage or early growth stage.
- ✎ Size of investments ranges up to EUR 1 million, in selected cases investments up to EUR 5 million are possible however.
- ✎ An average investment lasts between three and seven years.
- ✎ Portfolio value growth is realized by delivering financing that is necessary to develop the project as well as business and industry support.
- ✎ Currently, the portfolio of the fund includes seven companies, and the value of assets under management is close to 30 million PLN.
- ✎ Sectoral team competences, experience in startup entry, brand recognized as the leading biotech/med/pharma fund and the available experience of the MCI Group constitute the fund's leading position on the Polish market.

company	activity	investment date	current events
 Genomed®	Biotechnology, genetic diagnostics	23.01.2008	IPO on NewConnect (30 May this year)
 24med pogotowie ratunkowe	Private round-the-clock medical care	22.09.2008	Verification of business model and planned rollout
 4med centra medyczne	Chain of private medical centers	10.12.2008	Increasing capital engagement
 domzdrowia.pl® Więcej niż apteka	E-commerce, largest online pharmacy	(24.10.2005) 15.09.2010	Acquisition of company from the top 10 online pharmacies, planned additional financing
 MEDCASCO	Health insurance	20.07.2010	Signing agreement with T.U. Europa, market rollout of products
 BIOTECH VARSOVIA PHARMA	Innovative dietary supplements, health products for women	28.10.2010	Product reenters the market
 continuum care	Comprehensive eldercare	25.07.2011	Fund invests in the company

- ✎ Competent and experienced managers (several years' experience in running private healthcare in Poland on executive level).
- ✎ Business model of the company focused on comprehensive solutions meeting the needs of individual clients.
- ✎ Market with potential for growth due to demographic changes.
- ✎ Growing purchasing power of the target group – people aged 65+.
- ✎ Changes in public health care.

# disclaimer

This presentation shall not constitute an offer in the meaning of the law.

This presentation has been prepared based on the best knowledge of MCI Management SA and MCI.BioVentures and included actual data on the day it was published.



## **MCI.BioVentures**

ul. Bartoszowicka 3, 52-428 Wrocław

tel. +71 337 37 10, fax +71 337 37 11

e-mail: [bio@mci.eu](mailto:bio@mci.eu)

[www.bioventures.pl](http://www.bioventures.pl)

### **MCI Management SA**

Warszawskie Centrum Finansowe  
ul. Emilii Plater 53, 00-113 Warszawa  
tel. +22 540 73 80, fax +22 540 73 81  
e-mail: [office@mci.eu](mailto:office@mci.eu)  
[www.mci.pl](http://www.mci.pl)